Market Eyes LiveRecursion Pharmaceuticals, Inc. Class A (RXRX) Stock Rating & Analysis
MELANY's data-driven read on Recursion Pharmaceuticals, Inc. Class A · Biological Products, (No Diagnostic Substances).
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company that combines biology, chemistry, automation, data science, and engineering to decode biology and industrialize drug discovery. It operates in the United States, United Kingdom, and other regions, with most revenue derived from the United States.
Why RXRX scores 52/100
MELANY scores Recursion Pharmaceuticals, Inc. Class A 52/100 by weighing eight factors. Here is how RXRX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +5.3% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +14%
What Wall Street price targets and revisions are signalling.
- Analyst targets 110% upside
- Institutional net buying +5.1%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for RXRX
- Operating margin -1760%, cash-burn business, dependent on capital markets
- Negative free cash flow, company consuming cash, not generating it
- Short interest 35% of float, high volatility risk on news
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Recursion Pharmaceuticals, Inc. Class A sits in the Healthcare sector theme, which MELANY currently rates 51/100 for strength. Theme strength feeds RXRX's momentum and catalyst factors above.
RXRX trade plan (members only)
MELANY has a full position plan for Recursion Pharmaceuticals, Inc. Class A: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates RXRX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Recursion Pharmaceuticals, Inc. Class A's 52/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about RXRX
Is Recursion Pharmaceuticals, Inc. Class A (RXRX) a buy?
As of 2026-08-19, MELANY rated Recursion Pharmaceuticals, Inc. Class A Promising with a composite score of 52/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Recursion Pharmaceuticals, Inc. Class A's MELANY score?
Recursion Pharmaceuticals, Inc. Class A (RXRX) has a MELANY composite score of 52/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the RXRX stock rating calculated?
MELANY scores RXRX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Recursion Pharmaceuticals, Inc. Class A stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Recursion Pharmaceuticals, Inc. Class A (RXRX) Promising with a composite of 52/100 as of 2026-08-19. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the RXRX stock price forecast?
MELANY does not publish price targets or forecasts for RXRX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 52/100 across eight factors for Recursion Pharmaceuticals, Inc. Class A, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is RXRX stock overvalued or undervalued?
MELANY's valuation factor currently reads 67/100 for Recursion Pharmaceuticals, Inc. Class A, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives RXRX's read.
What price should I buy RXRX at?
Rather than chasing the current price, MELANY computes a smart entry zone for RXRX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying RXRX stock?
The top risks MELANY currently flags for Recursion Pharmaceuticals, Inc. Class A: Operating margin -1760%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 35% of float, high volatility risk on news; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Recursion Pharmaceuticals, Inc. Class A a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 24/100 for Recursion Pharmaceuticals, Inc. Class A, and earnings track record, at 91/100. The 52/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will RXRX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 43/100 for RXRX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this RXRX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-19. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores RXRX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
RXRX's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.